Related Experiment Video

Updated: Aug 22, 2026

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angiography

M Schumacher1, B Eber, A Tiran

  • 1Department of Internal Medicine, Karl Franzens University, Graz, Austria.

Cardiology
|January 1, 1992
PubMed

Insights

Fibrinogen is a known risk factor for coronary heart disease (CHD). However, this study found that fibrinogen levels do not predict restenosis after percutaneous transluminal coronary angioplasty (PTCA) in men.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Biochemistry

Background:

  • Fibrinogen is an established independent risk factor for coronary heart disease (CHD).
  • Restenosis following percutaneous transluminal coronary angioplasty (PTCA) is a significant limitation to the long-term success of the procedure.
  • The role of fibrinogen as a prognostic factor for restenosis after PTCA remains unclear.

Purpose of the Study:

  • To investigate whether plasma fibrinogen concentrations predict restenosis after successful PTCA in male patients with CHD.
  • To compare fibrinogen levels between patients who develop restenosis and those who do not.

Main Methods:

  • A cohort of 50 male patients with CHD and successful PTCA was studied.
  • Plasma fibrinogen levels were measured.
  • Follow-up coronary angiography was performed at 12 months post-PTCA to assess for restenosis.
  • Patient groups with and without restenosis were compared based on medical history, lipid profiles, and fibrinogen levels.

Main Results:

  • Twenty-two patients (44%) experienced restenosis, while 28 (56%) did not.
  • No significant differences were observed in medical history or routine lipid profiles between the restenosis and non-restenosis groups.
  • Mean fibrinogen levels were 405 +/- 128 mg/dl in the restenosis group and 352 +/- 94 mg/dl in the non-restenosis group (p > 0.05).
  • Elevated fibrinogen levels (>400 mg/dl) were present in 8 patients in each group.

Conclusions:

  • Despite being a risk factor for CHD, plasma fibrinogen concentration is not a significant prognostic factor for restenosis following PTCA in this cohort of men.
  • These findings suggest that other factors may be more critical in determining restenosis risk after PTCA.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Establishment and Evaluation of a Porcine Vein Graft Disease Model08:50

Establishment and Evaluation of a Porcine Vein Graft Disease Model

Published on: July 25, 2022

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...